Barclays initiated coverage of AbbVie (ABBV) with an Overweight rating and $275 price target The firm believes consensus estimates are underestimating AbbVie’s operating leverage potential. Barclays believes success in any of AbbVie’s proof-of-concept studies can drive multiple expansion for the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie’s ABBV-547 First‑in‑Human Trial: What Early Pipeline Moves Mean for ABBV Investors
- AbbVie’s VOLITE Skin Quality Trial Completion: What It Means for ABBV Investors
- AbbVie price target raised to $299 from $289 at Piper Sandler
- AbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch
- AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth